ArticlePloS one2016
The Circular RNA Cdr1as Act as an Oncogene in Hepatocellular Carcinoma through Targeting miR-7 Expression.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 211 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
211 citing papers in PubMed, 4 syntheses or guidelines pooled it, 389 citations in OpenAlex.
- Cross talk between bacterial and human gene networks enriched using ncRNAs in IBD disease.Scientific reports · 2023Pooled it
- Diagnostic and prognostic value of circular RNA CDR1as/ciRS-7 for solid tumours: A systematic review and meta-analysis.Journal of cellular and molecular medicine · 2020Pooled it
- Prognostic Value of Circular RNA ciRS-7 in Various Cancers: A PRISMA-Compliant Meta-Analysis.BioMed research international · 2020Pooled it
- The Prognostic and Predictive Significance of circRNA CDR1as in Tumor Progression.Frontiers in oncology · 2020Pooled it
- Retraction: The PU.1-Modulated MicroRNA-22 Is a Regulator of Monocyte/Macrophage Differentiation and Acute Myeloid Leukemia.PLoS genetics · 2026Article
- Retraction: MicroRNA-595 sensitizes ovarian cancer cells to cisplatin by targeting ABCB1.Oncotarget · 2026Article
- Noncoding RNAs in periodontitis: Progress and perspectives (Review).International journal of molecular medicine · 2025Review
- Retraction: MicroRNA-610 suppresses osteosarcoma oncogenicity via targeting TWIST1 expression.Oncotarget · 2025Article
- Role of circular RNAs in preeclampsia (Review).Experimental and therapeutic medicine · 2024Review
- CircRNA as an Achilles heel of cancer: characterization, biomarker and therapeutic modalities.Journal of translational medicine · 2024Review
- Non-coding RNAs as therapeutic targets in cancer and its clinical application.Journal of pharmaceutical analysis · 2024Review
- Circular RNA HSDL2 promotes breast cancer progression via miR-7978 ZNF704 axis and regulating hippo signaling pathway.Breast cancer research : BCR · 2024Article
- Circular RNA as a source of neoantigens for cancer vaccines.Journal for immunotherapy of cancer · 2024Article
- A therapeutical insight into the correlation between circRNAs and signaling pathways involved in cancer pathogenesis.Medical oncology (Northwood, London, England) · 2024Review
- Exploring non-coding RNA mechanisms in hepatocellular carcinoma: implications for therapy and prognosis.Frontiers in immunology · 2024Review
- MicroRNA-155 downregulates long noncoding RNA prostate cancer-associated transcript 29 in hepatocellular carcinoma to suppress cancer cell invasion and migration.Journal of biochemical and molecular toxicology · 2023Article
- mEpigenetics · 2023Article
- Emerging Role of Circular RNAs in Hepatocellular Carcinoma Immunotherapy.International journal of molecular sciences · 2023Review
- Roles and Molecular Mechanisms of Biomarkers in Hepatocellular Carcinoma with Microvascular Invasion: A Review.Journal of clinical and translational hepatology · 2023Review
- Role of Non-Coding RNAs in Hepatocellular Carcinoma Progression: From Classic to Novel Clinicopathogenetic Implications.Cancers · 2023Review
151 more citing papers are in PubMed but not listed here.
Corrections and comments
- Retraction · 2023-03-29Concerns/Issues about Authorship/Affiliation · Concerns/Issues about Image · Compromised Peer Review ·
- Retracted
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CircRNAs are a class of endogenous RNA that regulates gene expression at the post-transcriptional or transcriptionallevel through interacting with other molecules or microRNAs. Increasing studies have demonstrated that circRNAs play a crucial role in biology processes. CircRNAs are proved as potentialbiomarkers in many diseases including cancers. However, the role of Cdr1as in Hepatocellular carcinoma (HCC) remains to be elucidated. We demonstrated that Cdr1as expression was upregulated in HCC tissues compared with the adjacent non-tumor tissues. In addtion, miR-7 expression was downregulated in HCC tissues compared with the adjacent non-tumor tissues. Moreover, the expression level of miR-7 was inversely correlated with that in HCC tissues. Knockdown of Cdr1as suppressed the HCC cell proliferation and invasion. Overexpression of miR-7 inhibited the HCC cell proliferation and invasion. Overexpression of miR-7 could suppress the direct target gene CCNE1 and PIK3CD expression. Knockdown of Cdr1as suppressed the expression of miR-7 and also inhibited the CCNE1 and PIK3CD expression. Furthermore, knockdown of Cdr1as suppressed the HCC cell proliferation and invasion through targeting miR-7. These data suggested that Cdr1as acted as an oncogene partly through targeting miR-7 in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.